-
DE
Incretin Effect: Explanation & Role in Diabetes
The incretin effect describes the enhanced insulin secretion triggered by oral glucose intake compared to intravenous glucose. It plays a key role in blood sugar regulation.
Add as Preferred SourceThings worth knowing about "Incretin effect"
The incretin effect describes the enhanced insulin secretion triggered by oral glucose intake compared to intravenous glucose. It plays a key role in blood sugar regulation.
What is the Incretin Effect?
The incretin effect refers to the phenomenon whereby oral ingestion of glucose triggers a significantly greater release of insulin from the pancreas compared to the same amount of glucose administered intravenously. This difference is mediated by specialized gut hormones known as incretins. In healthy individuals, the incretin effect accounts for approximately 50–70 % of the total postprandial insulin response. In people with type 2 diabetes, this effect is markedly reduced, contributing to elevated blood sugar levels after meals.
The Main Incretin Hormones
Two hormones are primarily responsible for the incretin effect:
- GLP-1 (Glucagon-like Peptide-1): Secreted by L-cells in the small and large intestine. GLP-1 stimulates insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety.
- GIP (Glucose-dependent Insulinotropic Polypeptide): Released by K-cells in the duodenum and upper small intestine. GIP also stimulates insulin secretion in a glucose-dependent manner.
Both hormones are rapidly secreted into the bloodstream after food intake and are quickly broken down by the enzyme DPP-4 (Dipeptidyl Peptidase-4), limiting their biological activity to just a few minutes.
Mechanism of Action
When carbohydrates, fats, and proteins reach the small intestine, specialized enteroendocrine cells release GLP-1 and GIP into the bloodstream. These hormones travel to the pancreas and bind to specific receptors on the beta cells of the islets of Langerhans, triggering a glucose-dependent increase in insulin secretion. Because this stimulation only occurs when blood glucose is elevated, the risk of hypoglycemia (low blood sugar) under normal physiological conditions remains low.
In addition, GLP-1 inhibits the alpha cells of the pancreas, suppressing the release of glucagon, a hormone that raises blood glucose. This dual mechanism plays a crucial role in postprandial blood glucose control.
Clinical Relevance in Type 2 Diabetes
In patients with type 2 diabetes, the incretin effect is reduced to approximately 20 % of normal. Contributing factors include:
- Decreased GLP-1 secretion from intestinal cells
- Reduced responsiveness of beta cells to GIP
- Increased DPP-4 activity leading to faster hormone degradation
This impairment results in an insufficient insulin response to meals and contributes to postprandial hyperglycemia (elevated blood sugar after eating).
Therapeutic Use of the Incretin Effect
Understanding the incretin effect has led to the development of important diabetes medications:
- GLP-1 receptor agonists (e.g., semaglutide, liraglutide): These drugs mimic the action of native GLP-1 but are resistant to DPP-4 degradation, resulting in a longer duration of action. They lower blood glucose, promote weight loss, and have demonstrated cardiovascular benefits in clinical trials.
- DPP-4 inhibitors (gliptins, e.g., sitagliptin, saxagliptin): These agents inhibit the DPP-4 enzyme, thereby prolonging the activity of endogenous incretin hormones. They are well tolerated and carry a low risk of hypoglycemia.
Both drug classes are now among the cornerstone therapies in modern diabetes management.
Research Perspectives
The incretin effect is also of interest in other medical areas. Following bariatric surgery (e.g., Roux-en-Y gastric bypass), the incretin effect is markedly enhanced, which contributes to rapid improvement in glycemic control even before significant weight loss occurs. Furthermore, the roles of GLP-1 in appetite regulation, cardiovascular health, and neurological function are subjects of active research.
References
- Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. The Lancet Diabetes & Endocrinology, 2016; 4(6): 525–536.
- Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism, 2018; 27(4): 740–756.
- American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care, 2024; 47 (Supplement 1).
Building Blocks for a Healthy Life
As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.
Skip product gallery
Subscription available
Floral
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®30 lozenges
Regular price:
22,90 €
Discount
Subscription available
Lactoferrin 60 Capsules
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
60 Capsules
Sale price:
50,00 €
Regular price:
59,90 €
Subscription available
Multivitamin Mineral Complex
Daily basic supply: the complete spectrum of micronutrients
Natural multivitamin complex for the immune system, energy, and central body functions
30 Capsules
Regular price:
29,90 €
Subscription available
Natural Iron
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
30 Capsules
Regular price:
35,90 €